Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
FMR LLC and Abigail P. Johnson reported beneficial ownership of 5,707,883.15 shares of Travere Therapeutics, Inc. (TVTX) common stock, equal to 6.1% of the class. FMR LLC reported sole voting power over 4,978,969.83 shares, while Johnson reported 0.00 shares; both reported sole dispositive power over 5,707,883.15 shares.
Travere Therapeutics, Inc. (TVTX) reported third-quarter 2026 revenue of $224.563 million, versus $164.859 million a year earlier. Net product sales were $220.196 million, including $200.192 million from FILSPARI; license and collaboration revenue was $4.367 million, compared with $51.709 million. Travere recorded a net loss of $52.337 million, versus net income of $25.706 million.
For the first nine months, revenue was $521.345 million versus $361.039 million, while net loss was $124.236 million versus $28.275 million. Operating cash flow was $115.909 million, compared with $22.894 million used in the prior-year period. Travere recorded $113.115 million in in-process research and development expense related to civorebrutinib; its Everest agreement became effective in July 2026, with a $112.5 million upfront payment and up to $1.0 billion in additional milestones, plus royalties.
Travere issued $525.0 million of 0.50% convertible notes due 2032 and repurchased $221.4 million principal of 2029 notes for $350.9 million, including accrued interest. The remaining 2029 notes had $94.875 million principal outstanding at September 30, 2026.
Travere Therapeutics, Inc. reported third-quarter 2026 U.S. net product sales of $220.2 million, compared with $113.2 million a year earlier; FILSPARI contributed $200.2 million, with 120% year-over-year growth. Total revenue was $224.6 million versus $164.9 million. GAAP net loss was $52.3 million, or $0.55 per basic share, compared with net income of $25.7 million, or $0.29 per basic share. Travere recognized $113.1 million in IPR&D expense when it closed its civorebrutinib licensing and collaboration agreement with Everest Medicines.
Quarterly R&D expense was $70.3 million versus $51.9 million, and SG&A was $98.4 million versus $71.0 million. Cash, cash equivalents and marketable securities totaled $471.8 million as of September 30, 2026.
Travere said HARMONY topline data are anticipated in the second half of 2027 and a U.S. IND submission for civorebrutinib is planned by year-end. Bradley L. Campbell is to succeed Eric Dube, Ph.D., as president and CEO and join the Board of Directors effective December 1, 2026.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised options on October 15, 2026, acquiring 43,735 shares at $26.88 and 200,000 shares at $8.93. He sold 128,065 shares at a weighted average price of $52.9672, 37,270 at $54.1997, and 78,400 at $55.0179. Each sale was made under a written Rule 10b5-1(c) plan adopted June 16, 2026. The options expire January 21, 2031, and January 31, 2034, respectively.
Travere Therapeutics, Inc. (TVTX) reported a proposed sale by Eric Dube, identified as a director and officer, of 243,735 common shares, with an approximate sale date of October 15, 2026 and an aggregate market value of $12,983,763.45. The shares are identified as coming from the exercise of stock options; Morgan Stanley Smith Barney LLC is named as broker.
Travere Therapeutics, Inc. (TVTX) announced a planned leadership transition in which Eric Dube, Ph.D., will step down as President, Chief Executive Officer and Board member effective December 1, 2026, then serve as Executive Advisor through February 15, 2027 and as a consultant for up to 18 months. Bradley L. Campbell, formerly President and CEO of Amicus Therapeutics, will become President, CEO and a Board member as of the same date under an employment agreement that includes a $1,000,000 annual base salary, a target bonus of 85% of base salary, and initial equity awards valued at about $16.5 million in stock options and time-based RSUs, plus a further $3.75 million performance-based RSU grant expected in early 2027. Both Dr. Dube’s transition package and Mr. Campbell’s agreement include detailed vesting, consulting and severance protections, with enhanced equity acceleration and cash severance if a qualifying termination occurs around a Change in Control.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Research Officer, William E. Rote, exercised employee stock options for a total of 191,500 shares of common stock on September 15-16, 2026, at exercise prices including $15.46, $17.96, $25.25 and $26.88 per share. Over the same two days he sold an aggregate of 209,048 shares of common stock in open-market transactions at weighted average prices generally in the low-to-mid $60s per share. The sales were made pursuant to a written trading plan adopted on June 16, 2026, that meets the requirements of Rule 10b5-1(c), and the stock options exercised were reported as fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reported that EVP and Chief Commercial Officer Peter Heerma exercised employee stock options and sold shares of common stock over September 15–17, 2026. He exercised 258,189 options at strike prices between $8.93 and $26.88 per share and sold 283,189 shares of common stock in market transactions pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) executive Jula Inrig, EVP, Head of R&D & CMO, reported an option exercise and related share sales. On September 15, 2026, she exercised 32,395 employee stock options at $8.93 per share, receiving the same number of common shares, and subsequently sold 44,674 shares of common stock in a series of brokerage or private transactions at prices around the low-to-mid $60s per share. Following the option exercise, 43,605 options under that grant remain directly held and are scheduled to expire on January 31, 2034. The reported sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Legal Officer and General Counsel, Elizabeth E. Reed, exercised 37,500 stock options for common shares at an exercise price of $15.46 per share on September 15, 2026, then sold 37,500 common shares in multiple open-market transactions the same day. The option was fully vested and exercisable, and the sales were made pursuant to a written trading plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c).